Untitled Document

FierceBiotech Executive Summit: London

The leaders in biotech research and finance discuss new trends and events which are reshaping the industry.

Join FierceBiotech Editor-in-chief John Carroll at the Royal Society of Medicine London for an engaging half-day event, where we’ll gather the experts together to discuss venture fundraising in the UK, the IPO market and clinical trial design in an age of biopharma collaborations. We’ll round out the day with a networking cocktail hour.

Price:

Early Bird: £65 / $100 (through September 25th)
Standard Rate: £80 / $125
Please note, registration fees will be collected in US dollars. Price may vary slightly due to currency rates.

October 12, 2015
13:00-18:30

Royal Society of Medicine
1 Wimpole St,
Guy Whittle Auditorium
London W1G 0AE, United Kingdom

Panel: Megafunds, the X Factor and New Money

Biotech investors and CEOs discuss some of the big, and little funding ideas that are starting to pump more money into new and growing companies. What kind of returns (the X factor) are investors looking for, where can finance be accessed and what ideas are attracting the most new cash? Can the LSE offer the best opportunity for going public, or will Nasdaq continue to dominate the discussion in the UK and Europe?

Moderator:

Speakers:

   

John Carroll
Editor-in-Chief
FierceBiotech


Tim Haines
Managing Partner
Abingworth


Rafaèle Tordjman
Managing Partner
Sofinnova


Alex Pasteur, Ph.D.
Partner
Fidelity Biosciences


Gareth Powell
Fund Manager
Polar Capital

Fireside chat: A biotech bubble, or a strong bull market?

FierceBiotech Editor John Carroll and top analysts will take a look at the latest trends in biotech financing and IPOs on both sides of the Atlantic, as UK biotechs choose between Nasdaq and the LSE even as few U.S. biotechs look to British investors for their offerings. The overview will include a detailed review of just how much crossover cash has become available, a look at the debate over a potential bubble in the U.S. along with an analysis of the sustainability of the current wave of investor cash that’s now lifting biotech boats around the world.

Speakers:


Sam Fazeli
Senior Pharmaceutical Analyst
Bloomberg Intelligence


Nooman Haque
Director of Life Sciences & Healthcare
Silicon Valley Bank, UK

Panel: Clinical Trial Design in an Age of Biopharma Collaborations

Big and little biotech companies have been coming together in a tsunami of industry collaborations. How are these deals being fashioned to improve the chances of success in the clinic and what can partners do in the deal-making phase to design the most efficient clinical pathway for an experimental drug. The panel discussion will cover R&D in the collaborative process, and how CROs and other partners figure in to this discussion on Phase I through Phase III development — before the deal is signed.

Moderator:

Speakers:

   

John Carroll
Editor-in-Chief
FierceBiotech

Rafael Amado
Chief Medical Officer
Adaptimmune

Johan Verbeeck
Senior Director,
Johnson & Johnson


Mene Pangalos
Executive VP
AstraZeneca


Malcolm Weir
CEO
Heptares


Olav Hellebo
CEO
ReNeuron

Schedule:

13:00 – 13:45: Registration and Networking
13:45 – 14:05: Introduction and Opening Remarks
14:05 – 14:15: Welcome Address
14:15 – 15:15: Panel: Megafunds, the X Factor and New Money
15:15 – 15:30: Coffee Break
15:30 – 16:20: Fireside chat: A biotech bubble, or a strong bull market?
16:20 – 17:20: Panel: Clinical Trial Design in an Age of Biopharma Collaborations
17:20 – 17:30: Closing Address
17:30 – 18:30: Reception and Networking

FierceBiotech appreciates the support of the Communications Strategy Group in organizing this conference.

Questions? Please email [email protected]

Venue:

The Royal Society of Medicine
1 Wimpole St,
Guy Whittle Auditorium
London W1G 0AE, United Kingdom

Sponsor:




United BioSource Corporation (UBC) is a leading provider of pharmaceutical support services, partnering with life science companies to make medicine and medical products safer and more accessible. Our diverse suite of services helps bridge the gap between development and delivery and builds brand loyalty through patient access and adherence. UBC is well known for our ability to generate authoritative, real-world evidence of product effectiveness, safety, and value to assist healthcare decisions and enhance patient care.